# Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test

Source: https://onco.cc/trials/nct07340567/  
OnCo record `nct07340567` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and fOLFIRINOX / mFOLFIRINOX in colorectal cancer, run by UNICANCER, active but no longer recruiting.

## Summary

Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test is a phase 3, randomised interventional study registered as NCT07340567 by UNICANCER, with a registry enrolment figure of 2450 participants, started 2026-07-20 and due to reach its primary completion in 2032-11-01. Interventions recorded: Capecitabine; Oxaliplatin; Folfirinox; FOLFOX regimen. Conditions listed: Colorectal Cancer. Primary outcome: Non-inferiority of 6-month CAPE vs 3-month CAPOX ACT in terms of 3-year Disease Free Survival ctDNA-negative cohort; Superiority of 6-month FOLFIRINOX vs 6-month FOLFOX ACT in terms of 3-year Disease Free Survival ctDNA-positive cohort. Colorectal eligibility wording from the registry: "Histologically confirmed stage III pMMR/MSS colon and high rectum adenocarcinoma (T, N1 or N2, M0) excluding medium and low rectal cancers (≥12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery are still eligible), without gross or microscopic evidence of residual". Sites: France, Sweden. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: CIRCULATEIII
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07340567
- Phase: 3
- Setting: Tailoring the Decision for Adjuvant Chemotherapy Using Circulating Tumour DNA, in Patients With Stage III Colorectal Cancer
- Sponsor: UNICANCER
- Enrolled: 2450

## Sources

- ClinicalTrials.gov NCT07340567: https://clinicaltrials.gov/study/NCT07340567

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- companies: [Natera](https://onco.cc/companies/natera/), [UNICANCER](https://onco.cc/companies/unicancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07340567.json